Drug Approval | February 26, 2026
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Nadda underlined that India’s policy framework is aligned with this transformation
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Subscribe To Our Newsletter & Stay Updated
